
An immunologic approach besides surgical, radiotherapeutic, chemotherapeutic methods in the treatment of cancer was proposed for the first time by Paul Ehrlich in 1906. The structure, produced by conjugating the antibodies against the tumor cells with a toxin molecule by Moolten and Cooperband (1970) was named as Immunotoxins. Producing antibodies with the desired amount and purity was achieved by improving the Hybridoma technology, Immunotoxins were tried to be produced by conjugating the monoclonal antibodies with the different toxic agents. Removing the receptor binding region of the toxin molecule was demonstrated to be more effective although good results were obtained from the studies utilising the toxin of Corynebacterium diphtheriae. Toxin production with the desired amount and structure was accomplished by the improved genetic methods. Although in vivo applications of the immunotoxins are still limited, it is believed that they will be important therapeutic agents in the future.
Hybridomas, Immunotoxins, Neoplasms, Animals, Antibodies, Monoclonal, Humans
Hybridomas, Immunotoxins, Neoplasms, Animals, Antibodies, Monoclonal, Humans
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
